PYPD
PolyPid Announces Positive Recommendation by Dsmb to Continue Enrollment of Phase 3 Shield Ii Trial of D-Plex₁₀₀ to 800 Patients With a Concurrent Private Placement of up to $41 Million
时间：2024-12-24 08:22:34 市场： 美股 综合
PolyPid Announces Receipt of Nasdaq Notification of Minimum Stockholders’ Equity Non-Compliance
时间：2024-11-30 02:05:00 市场： 美股 综合
PolyPid Ltd: Entered Into a Sales Agreement, With Oppenheimer & Co. Inc.
时间：2024-11-09 05:23:35 市场： 美股 综合
PolyPid Ltd. : Craig-Hallum Initiates Coverage With Buy Rating and Target Price $10
时间：2024-11-04 20:17:02 市场： 美股 综合
PolyPid Ltd - Last Patient in for Planned Unblinded Interim Analysis in Ongoing Shield Ii Phase 3 Trial Evaluating D-Plex₁₀₀
时间：2024-10-01 19:01:57 市场： 美股 综合
PolyPid Ltd - Top-Line Results Anticipated in Q1 of 2025
时间：2024-10-01 19:01:57 市场： 美股 综合